PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16341932-2	2005	In addition, we studied the inhibition of paroxetine binding to SERT by quipazine and N-methyl-quipazine (NMQ).	Quipazine	72-81	solute carrier family 6 member 4	Rattus norvegicus	64-68
17084866-7	2007	This study shows that the 5-HT(3) receptor mediates the resetting effects of quipazine on locomotor activity rhythms.	Quipazine	77-86	5-hydroxytryptamine receptor 3A	Rattus norvegicus	26-42
17084866-8	2007	The 5-HT(3) receptor is only partially implicated in quipazine-induced expression of c-FOS, while NMDA receptor inhibition blocks quipazine photic-like effects on both parameters.	Quipazine	53-62	5-hydroxytryptamine receptor 3A	Rattus norvegicus	4-20
17084866-8	2007	The 5-HT(3) receptor is only partially implicated in quipazine-induced expression of c-FOS, while NMDA receptor inhibition blocks quipazine photic-like effects on both parameters.	Quipazine	53-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-90
16138260-3	2005	Pretreatment with alpha-helical CRH, a CRH antagonist, significantly attenuated quipazine-induced hyperglycemia.	Quipazine	80-89	corticotropin releasing hormone	Rattus norvegicus	32-35
16138260-3	2005	Pretreatment with alpha-helical CRH, a CRH antagonist, significantly attenuated quipazine-induced hyperglycemia.	Quipazine	80-89	corticotropin releasing hormone	Rattus norvegicus	39-42
16138260-4	2005	Pretreatment with two different 5-HT3 receptor antagonists, LY-278,584 and ondansetron, was also able to produce a significant reduction in the hyperglycemic response evoked by central administration of quipazine.	Quipazine	203-212	5-hydroxytryptamine receptor 3A	Rattus norvegicus	32-46
16138260-7	2005	We conclude that acute pharmacological serotonergic stimulation by quipazine produces hyperglycemia by mechanisms that require the functional integrity of both CRH and 5-HT3 receptors, and that impairment in insulin secretion and/or activity may explain hyperglycemia induced by third ventricle injections of quipazine.	Quipazine	67-76	corticotropin releasing hormone	Rattus norvegicus	160-163
15848758-0	2005	Structure-affinity relationship studies on arylpiperazine derivatives related to quipazine as serotonin transporter ligands.	Quipazine	81-90	solute carrier family 6 member 4	Homo sapiens	94-115
15848758-2	2005	A series of quipazine derivatives, previously synthesized to probe the 5-HT(3) receptor, was evaluated for its potential interaction with serotonin transporter (SERT).	Quipazine	12-21	solute carrier family 6 member 4	Homo sapiens	138-159
15848758-2	2005	A series of quipazine derivatives, previously synthesized to probe the 5-HT(3) receptor, was evaluated for its potential interaction with serotonin transporter (SERT).	Quipazine	12-21	solute carrier family 6 member 4	Homo sapiens	161-165
15848758-3	2005	Some of them show nanomolar affinity for the rodent SERT comparable to or slightly higher than quipazine or N-methylquipazine.	Quipazine	95-104	solute carrier family 6 member 4	Homo sapiens	52-56
15848758-5	2005	The structure-affinity relationships obtained provided information on the role of the fused benzene ring of quipazine in the interaction with the SERT binding site and on the stereoelectronic requirements for the interaction of both the heteroaromatic component and the basic moiety.	Quipazine	108-117	solute carrier family 6 member 4	Homo sapiens	146-150
16084651-4	2005	Indeed, systemic as well as local administrations of the serotonin agonist quipazine in the region of the suprachiasmatic nucleus mimic the effects of light on the circadian system of rats, i.e. they induce phase-advances of the locomotor activity rhythm as well as c-FOS expression in the suprachiasmatic nucleus during late subjective night.	Quipazine	75-84	steroid sulfatase	Rattus norvegicus	263-267
16084651-4	2005	Indeed, systemic as well as local administrations of the serotonin agonist quipazine in the region of the suprachiasmatic nucleus mimic the effects of light on the circadian system of rats, i.e. they induce phase-advances of the locomotor activity rhythm as well as c-FOS expression in the suprachiasmatic nucleus during late subjective night.	Quipazine	75-84	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	268-271
12937671-3	2003	Intrathecal administration of 5-HT3 receptor agonist quipazine (200 mg) abolished nociceptive flexion reflex and alleviated spinal pain syndrome produced by impairment of GABAergic inhibition in the lumbar spinal segments.	Quipazine	53-62	5-hydroxytryptamine receptor 3A	Rattus norvegicus	30-44
12235534-9	2002	In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+/-11.7% of pre-injury value).	Quipazine	13-22	5-hydroxytryptamine receptor 2A	Rattus norvegicus	26-32
12693869-7	2003	In mice, quipazine modestly increased c-Fos expression in the SCN (site of the circadian pacemaker) during the subjective day, whereas 8-OH-DPAT did not affect SCN c-Fos.	Quipazine	9-18	FBJ osteosarcoma oncogene	Mus musculus	38-43
11817504-6	2002	Further, clozapine-induced hyperphagia was significantly (P<.05) reversed after treatment with SKF 38393 (dopamine D1 agonist), quinpirole (dopamine D2 agonist) and quipazine (5-HT1B, 5-HT2 and 5-HT3 agonist).	Quipazine	168-177	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	179-185
10574568-3	1999	Previous work from this laboratory demonstrated that systemic administrations of the serotonin agonist quipazine mimic the effects of light on the circadian system of rats, i.e. they induce photic-like phase shifts of the circadian activity rhythm as well as c-Fos expression in the SCN.	Quipazine	103-112	steroid sulfatase	Rattus norvegicus	256-260
11103883-5	2000	This suggests that the MK 212 discriminative stimulus is mediated by 5-HT2C receptors, while quipazine-induced head twitches are mediated primarily by 5-HT2A receptors.	Quipazine	93-102	5-hydroxytryptamine receptor 2A	Rattus norvegicus	151-157
10574568-3	1999	Previous work from this laboratory demonstrated that systemic administrations of the serotonin agonist quipazine mimic the effects of light on the circadian system of rats, i.e. they induce photic-like phase shifts of the circadian activity rhythm as well as c-Fos expression in the SCN.	Quipazine	103-112	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	261-264
9739147-1	1998	The serotonin agonist quipazine has been shown to cause phase shifts in melatonin and activity rhythms and to induce c-fos in the suprachiasmatic nucleus of rats.	Quipazine	22-31	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	117-122
10516629-18	1999	quipazine and DOI are primarily due to activation of central 5-HT2A receptors, which causes the release of vasopressin and a tachycardia.	Quipazine	0-9	arginine vasopressin	Rattus norvegicus	107-118
10194650-0	1999	Serotonin agonist quipazine induces photic-like phase shifts of the circadian activity rhythm and c-Fos expression in the rat suprachiasmatic nucleus.	Quipazine	18-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	98-103
10194650-3	1999	Furthermore, they investigated the effect of quipazine on the expression of c-Fos in the mammalian circadian pacemaker, the suprachiasmatic nucleus (SCN).	Quipazine	45-54	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	76-81
10194650-5	1999	More important, quipazine induced significant phase advances of the activity rhythm and c-Fos production in the SCN at the end of the subjective night (Circadian Time [CT] 22), whereas neither phase shifts nor c-Fos induction were observed during the subjective day.	Quipazine	16-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	88-93
10527123-6	1999	Serotonin agonist quipazine increased GH levels but failed to enhance the stimulatory effect of melatonin.	Quipazine	18-27	somatotropin	Coturnix japonica	38-40
9751178-2	1998	Treatment of A1A1 variant cells, which express the 5-HT2A receptor coupled to the stimulation of phosphatidylinositol (PI) hydrolysis, with antisense oligodeoxynucleotide decreased the maximal stimulation of PI hydrolysis by the partial agonist quipazine and the number of 5-HT2A receptor sites as measured by the binding of 2-[125I]-iodolysergic acid diethylamide.	Quipazine	245-254	5-hydroxytryptamine receptor 2A	Homo sapiens	51-66
8891601-0	1996	Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.	Quipazine	95-104	5-hydroxytryptamine receptor 2A	Rattus norvegicus	15-21
9726627-2	1998	TCE at millimolar concentrations increased the magnitude of the 5-HT3 receptor-mediated depolarisations of the rat vagus nerve by a number of agonists (5-HT, phenylbiguanide (PBG), quipazine).	Quipazine	181-190	5-hydroxytryptamine receptor 3A	Rattus norvegicus	64-78
9313909-0	1997	Quipazine and light have similar effects on c-fos induction in the rat suprachiasmatic nucleus.	Quipazine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	44-49
9313909-1	1997	The effects of the serotonin agonist, quipazine, on the induction of c-fos in the suprachiasmatic nucleus of the rat was examined at different times of the 24 h cycle.	Quipazine	38-47	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	69-74
9313909-2	1997	Quipazine administered at night induced Fos production in a dose dependent manner (1, 3, 10, 30 mumol/kg) in the ventrolateral portion of the suprachiasmatic nucleus at ZT18.	Quipazine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-43
9313909-4	1997	When compared to the effects of light pulses (2 lux/1 min), quipazine only caused c-fos induction at times when light caused induction.	Quipazine	60-69	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	82-87
9500663-6	1997	When the non-specific serotonin agonist quipazine was administered at CT 18, it mimicked both the acute and phase delaying effects of light on melatonin secretion and induced c-Fos in the SCN with a regional distribution identical to that observed following light treatment.	Quipazine	40-49	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	175-180
7657159-5	1995	Quipazine increased plasma PRL levels from 26.8 +/- 7.1 ng/ml at Time 0 to a peak value of 148.1 +/- 31.4 ng/ml 2 hr after infection.	Quipazine	0-9	prolactin	Meleagris gallopavo	27-30
8584618-8	1995	These results suggest that quipazine and lisuride substitute for the stimulus properties of the phenylalkglamine hallucinogen (-)DOM via agonist activity at 5-HT2A receptors.	Quipazine	27-36	5-hydroxytryptamine receptor 2A	Homo sapiens	157-163
7473132-7	1995	The combined results from the substitution, antagonism and ex vivo receptor autoradiographic studies suggest that the discriminative stimuli of quipazine and ketanserin are mediated at least in part by the 5-HT2A receptor.	Quipazine	144-153	5-hydroxytryptamine receptor 2A	Rattus norvegicus	206-212
7657159-6	1995	Pretreatment with methysergide or VIP-immunoneutralization abolished the PRL response to quipazine.	Quipazine	89-98	VIP peptides	Meleagris gallopavo	34-37
7657159-6	1995	Pretreatment with methysergide or VIP-immunoneutralization abolished the PRL response to quipazine.	Quipazine	89-98	prolactin	Meleagris gallopavo	73-76
7875557-7	1994	Chronic treatment with the agonists quipazine and trifluoromethylphenylpiperazine (TFMPP) and the antagonists ritanserin and methiothepin significantly down-regulated brainstem 5-HT1C sites, which were 65% of [3H]mesulergine-labeled sites in brainstem.	Quipazine	36-45	5-hydroxytryptamine receptor 2C	Rattus norvegicus	177-183
7541281-18	1995	Quipazine (1 nM-0.3 microM) antagonized 5-HT evoked currents recorded from oocytes expressing the 5-HT3R-A subunit with an IC50 of 18 +/- 3 nM(n = 4).	Quipazine	0-9	5-hydroxytryptamine (serotonin) receptor 3A	Mus musculus	98-104
7883142-7	1994	Plasma prolactin concentrations were increased after intravenous administration of chicken vasoactive intestinal polypeptide or quipazine, a 5-HT agonist.	Quipazine	128-137	prolactin	Gallus gallus	7-16
7859924-12	1994	VIP mRNA levels rose significantly on day 1 of quipazine treatment but thereafter fell to a minimum of 22% (1.0 kb) and 52% (1.7 kb) of control by day 14.	Quipazine	47-56	vasoactive intestinal peptide	Rattus norvegicus	0-3
1350069-6	1992	LEW/N hypothalami released less immunoreactive CRH (iCRH) in response to ACh, NE, 5-HT and quipazine than F344/N hypothalami.	Quipazine	91-100	corticotropin releasing hormone	Rattus norvegicus	47-50
7984042-4	1994	This study was designed to investigate whether the SCN display a rhythm of c-fos mRNA levels in vitro and whether quipazine, which phase-shifts the SCN circadian clock, induces c-fos expression in vitro.	Quipazine	114-123	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	177-182
7984042-7	1994	Quipazine treatment during the subjective day (which phase-advances the circadian rhythm of neuronal firing in the SCN) decreased c-fos mRNA levels in the dorsomedial but not ventrolateral SCN, but quipazine did not affect c-fos levels when administered at night.	Quipazine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	130-135
7984042-7	1994	Quipazine treatment during the subjective day (which phase-advances the circadian rhythm of neuronal firing in the SCN) decreased c-fos mRNA levels in the dorsomedial but not ventrolateral SCN, but quipazine did not affect c-fos levels when administered at night.	Quipazine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	223-228
7945736-5	1994	The putative 5-HT1B agonist (m-trifluoromethyl-phenylpiperazine (TFMPP), but not [1-(3-chlorophenyl)piperazine] (m-CPP) or the 5-HT1B antagonists pindolol or quipazine, reduced the Bmax of cortical 5-HT1B sites (-16%).	Quipazine	158-167	5-hydroxytryptamine receptor 1B	Rattus norvegicus	13-19
8152532-3	1993	Quipazine, an agonist at 5-HT1B/1C/2 receptors, significantly increased avoidance responding in a dose-dependent manner (1.25-10 mg/kg, s.c.).	Quipazine	0-9	5-hydroxytryptamine receptor 1B	Rattus norvegicus	25-31
8152532-9	1993	These results suggest that quipazine increases the conditioned avoidance behaviour by an action that might be mediated through stimulation of 5-HT1C receptors.	Quipazine	27-36	5-hydroxytryptamine receptor 2C	Rattus norvegicus	142-148
8434056-0	1993	Further evidence that prolactin secretion in adult female rats is differently modified after neonatal estrogenization or androgenization: responses to methysergide, quipazine, and pizotifen.	Quipazine	165-174	prolactin	Rattus norvegicus	22-31
8199864-1	1994	In previous studies, we showed that light-induced Fos protein expression in the ventrolateral SCN is markedly inhibited by the nonselective serotonergic, quipazine.	Quipazine	154-163	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	50-53
8041227-3	1994	Nefazodone weakly antagonized the quipazine-induced rise in rat serum corticosterone levels and the quipazine-induced increase in rat hypothalamic 3-methoxy-4-hydroxy-phenylglycol sulfate, suggesting blockade of 5HT2A receptors in vivo.	Quipazine	100-109	5-hydroxytryptamine receptor 2A	Rattus norvegicus	212-217
7904818-5	1993	Binding studies at 5-HT receptors indicated that the quipazine analogue, compound I, has moderate affinity for the selective 5-HT1D ligand while the trazodone analogue, compound II, binds to 5-HT2 receptors.	Quipazine	53-62	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	125-131
8220179-5	1993	The binding had the pharmacological properties of a 5HT3 receptor, being potently inhibited by a variety of 5HT3 agonists and antagonists including (S)-zacopride (Ki = 0.032 nM), Quipazine (Ki = 0.45 nM), LY278584 (Ki = 0.5 nM), (1-m-chlorophenyl)-biguanide (Ki = 0.6 nM) and ICS 205-930 (Ki = 1.0 nM).	Quipazine	179-188	5-hydroxytryptamine receptor 3A	Rattus norvegicus	52-65
7902183-3	1993	injection of the serotonergic, quipazine, caused a marked decrease in the number of SCN cells expressing Fos protein-like immunoreactivity (Fos-LI) induced by a light pulse delivered during the latter part of the dark phase (7 h after lights-off; 55.6 +/- 7.5% of vehicle controls, P < 0.004).	Quipazine	31-40	proto-oncogene c-Fos	Mesocricetus auratus	105-108
7902183-3	1993	injection of the serotonergic, quipazine, caused a marked decrease in the number of SCN cells expressing Fos protein-like immunoreactivity (Fos-LI) induced by a light pulse delivered during the latter part of the dark phase (7 h after lights-off; 55.6 +/- 7.5% of vehicle controls, P < 0.004).	Quipazine	31-40	proto-oncogene c-Fos	Mesocricetus auratus	140-143
7902183-5	1993	In a likewise manner, intra-SCN microinjection of quipazine inhibited light-induced Fos-LI in the ventrolateral SCN, indicating that the suppressive action of quipazine is centered in the SCN.	Quipazine	50-59	proto-oncogene c-Fos	Mesocricetus auratus	84-87
8490207-12	1993	Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects.	Quipazine	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	23-29
8490207-12	1993	Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects.	Quipazine	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	76-82
8490207-12	1993	Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects.	Quipazine	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	76-82
8490207-14	1993	This suggests that quipazine acts on 5-HT1A receptors in the daytime to advance the SCN clock.	Quipazine	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43
19215503-2	1991	The serotonin (5-HT) precursor 5-hydroxy-L-tryptophan (5-HTP) and the 5-HT receptor agonist quipazine maleate stimulated serum GH levels in 2-day-old rat pups separated from their mothers for 6 h. The increase in serum GH during suckling was further elevated by 5-HTP.	Quipazine	92-109	gonadotropin releasing hormone receptor	Rattus norvegicus	127-129
1573708-0	1992	Effects of metoclopramide and quipazine on serum prolactin concentrations in steers.	Quipazine	30-39	prolactin	Homo sapiens	49-58
1559139-8	1992	Competition curves generated with increasing concentrations of quipazine, PBG, 5-HT and 2-methyl-5-HT displayed Hill coefficients greater than unity when the 5-HT3 receptor recognition sites in the entorhinal cortex preparation were labelled with [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330.	Quipazine	63-72	5-hydroxytryptamine receptor 3A	Rattus norvegicus	158-172
19215503-2	1991	The serotonin (5-HT) precursor 5-hydroxy-L-tryptophan (5-HTP) and the 5-HT receptor agonist quipazine maleate stimulated serum GH levels in 2-day-old rat pups separated from their mothers for 6 h. The increase in serum GH during suckling was further elevated by 5-HTP.	Quipazine	92-109	gonadotropin releasing hormone receptor	Rattus norvegicus	219-221
1830236-13	1991	5-HT3 receptor antagonists competed for [3H]-quipazine binding with high nanomolar affinities in the three preparations and the rank order of affinity was: (S)-zacopride > quarternized ICS 205-930 2 granisetron > ondansetron > ICS 205-209 (R)-zacopride > quipazine > renzapride > MDL-72222 > butanopride > metoclopramide.	Quipazine	45-54	5-hydroxytryptamine receptor 3A	Rattus norvegicus	0-14
1812298-0	1991	Improvement of 5-HT3 receptor binding assay: enhancement of specific [3H]quipazine binding with Triton X-100-treated membranes from rat cortex.	Quipazine	73-82	5-hydroxytryptamine receptor 3A	Rattus norvegicus	15-29
1830236-18	1991	In conclusion, [3H]-quipazine labelled 5-HT3 receptor sites in homogenates of NG108-15 cells, NCB-20 cells and rat cerebral cortex.	Quipazine	20-29	5-hydroxytryptamine receptor 3A	Rattus norvegicus	39-53
2319481-9	1990	Chronic administration of the 5-HT agonist quipazine produced a 32% loss of 5-HT1c binding sites in the choroid plexus, with no change in the 5-HT-induced phosphoinositide hydrolysis response.	Quipazine	43-52	5-hydroxytryptamine receptor 2C	Rattus norvegicus	76-82
2148812-1	1990	The serum corticosterone concentration in rats was increased by injection of quipazine, a relatively nonselective serotonin (5-hydroxytryptamine; 5-HT) agonist, or 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT), a serotonin agonist selective for the 5-HT1A subtype of receptor.	Quipazine	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	255-261
2303819-8	1990	Various antagonists completed for the soluble receptors with a rank order of potency typical for binding at a 5-HT3 receptor site: zacopride (Ki = 0.26 nM) greater than quipazine (0.37 nM) = Q ICS 205-930 (0.33 nM) greater than ICS 205-930 (0.93 nM) greater than GR 38032F (2.2 nM) greater than BRL 24924 (4.1 nM) greater than MDL 72222 (23.4 nM) greater than ketanserin (6,000 nM).	Quipazine	169-178	5-hydroxytryptamine receptor 3A	Rattus norvegicus	110-124
2166792-1	1990	This study investigates the possibility that mianserin, a serotonin-2 (5HT2) receptor antagonist, produces a prolonged antagonism of quipazine discrimination, consistent with its prolonged biochemical effects.	Quipazine	133-142	5-hydroxytryptamine receptor 2A	Rattus norvegicus	58-85
1688963-0	1990	Quipazine increases renin release by a peripheral hemodynamic mechanism.	Quipazine	0-9	renin	Rattus norvegicus	20-25
2097103-5	1990	5-HT or quipazine, however, could still induce significant PRL secretion on top of the increased PRL levels.	Quipazine	8-17	prolactin	Rattus norvegicus	59-62
2097103-5	1990	5-HT or quipazine, however, could still induce significant PRL secretion on top of the increased PRL levels.	Quipazine	8-17	prolactin	Rattus norvegicus	97-100
2138331-2	1990	This hypothesis was tested by examining the effect of various 5-HT1A agonists on the 5-HT2 receptor-mediated quipazine-induced head shake response in rats.	Quipazine	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
3320345-0	1987	Activation of serotonin2 (5-HT2) receptors by quipazine increases arterial pressure and renin secretion in conscious rats.	Quipazine	46-55	renin	Rattus norvegicus	88-93
2524399-6	1989	), a specific antagonist of 5-HT2 receptors, administered 1 h before the administration of d-fenfluramine or quipazine, completely prevented the PRL-releasing effect of these drugs.	Quipazine	109-118	prolactin	Rattus norvegicus	145-148
2845440-3	1988	In Experiment 1, quipazine (serotonin type II agonist) was found to significantly attenuate the short-term effect of MSH while only partially attenuating the long-term action of MSH.	Quipazine	17-26	proopiomelanocortin	Rattus norvegicus	117-120
2467272-3	1988	Pretreatment of rats with the serotonin agonist, quipazine (10 mg/kg ip) caused increase in serum prolactin levels.	Quipazine	49-58	prolactin	Rattus norvegicus	98-107
2467272-4	1988	Depletion of serotonin stores by pretreatment with p-chloro-phenylalanine methyl-ester (PCPA; 3 x 300 mg/kg ip) significantly prevent the effect of quipazine on prolactin levels.	Quipazine	148-157	prolactin	Rattus norvegicus	161-170
3320345-1	1987	Quipazine, a nonselective serotonin (5-HT) agonist, has been shown to increase plasma renin activity (PRA).	Quipazine	0-9	renin	Rattus norvegicus	86-91
3320345-10	1987	Total blockade of quipazine-induced renin secretion was produced by LY 53857 at 0.003 mg/kg, and the response was still reduced by 50% at 0.001 mg/kg.	Quipazine	18-27	renin	Rattus norvegicus	36-41
3320345-12	1987	The 10-fold difference in the dose of LY 53857 necessary to block the pressor and renin responses may be due to subtle differences in receptor subtypes, or to pharmacokinetic properties favoring antagonism of quipazine-induced renin secretion.	Quipazine	209-218	renin	Rattus norvegicus	227-232
3663239-6	1987	Quipazine, a putative specific 5-HT2 agonist, appeared to be only 3-fold more potent at 5-HT2 than at 5-HT1A receptors when [3H]ketanserin was used as the 5-HT2 radioligand.	Quipazine	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	102-108
2885213-0	1987	Somatostatin immunoneutralization overcomes the inhibitory effects of quipazine and pargyline on growth hormone secretion in domestic fowl.	Quipazine	70-79	growth hormone	Gallus gallus	97-111
3663239-7	1987	When [3H]DOB was used as the 5-HT2 radioligand, quipazine was determined to be 100-fold more potent at 5-HT2 receptors than at 5-HT1A receptors.	Quipazine	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	127-133
2885213-1	1987	The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity.	Quipazine	40-49	growth hormone	Gallus gallus	61-75
3031276-7	1987	Unlike PRL, corticosterone and growth hormone secretion were stimulated by quipazine and 5-hydroxytryptophan plus fluoxetine in both adult and neonatal rats.	Quipazine	75-84	gonadotropin releasing hormone receptor	Rattus norvegicus	31-45
2885213-1	1987	The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity.	Quipazine	40-49	somatostatin 1	Gallus gallus	160-164
2885213-1	1987	The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity.	Quipazine	40-49	somatostatin 1	Gallus gallus	172-176
2885213-3	1987	These results suggest that peptides with SRIF-14 or SRIF-28(1-14)-like immunoreactivity tonically inhibit GH secretion and are at least partially responsible for the inhibitory effects of pargyline and quipazine on GH release in immature domestic fowl.	Quipazine	202-211	somatostatin 1	Gallus gallus	41-45
3031276-4	1987	In contrast, the serotonin agonists, quipazine and m-chlorophenylpiperazine, and the serotonin-releasing drug p-chloroamphetamine produced dose-related increases in PRL release in adult rats, but not in neonatal rats.	Quipazine	37-46	prolactin	Rattus norvegicus	165-168
3497800-3	1987	In contrast, chronic treatment of rats with dexamethasone resulted in a potentiation of the PRL response to quipazine, 5-hydroxytryptophan and haloperidol.	Quipazine	108-117	prolactin	Rattus norvegicus	92-95
3497800-1	1987	Basal serum concentrations of prolactin (PRL) and the elevation of serum PRL concentrations induced by the serotonergic agents, quipazine and 5-hydroxytryptophan (5-HTP) were suppressed in rats treated acutely with dexamethasone.	Quipazine	128-137	prolactin	Rattus norvegicus	73-76
2881309-0	1987	Quipazine-metoclopramide inhibition of CB-154-induced prolactin suppression in rats: neurotransmitter-metabolite correlations.	Quipazine	0-9	prolactin	Rattus norvegicus	54-63
2881309-5	1987	Increased turnover of dopamine and decreased turnover of serotonin correlate with elevated prolactin concentrations for quipazine and metoclopramide administered together.	Quipazine	120-129	prolactin	Rattus norvegicus	91-100
2881309-6	1987	The combination of quipazine and metoclopramide protects rats against CB-154-induced prolactin suppression better than either of the drugs given alone.	Quipazine	19-28	prolactin	Rattus norvegicus	85-94
2853663-7	1987	Quipazine injected iv at .1 or .5 mg/kg BW increased plasma GH (P less than .05) and ACTH (P less than .001) concentrations.	Quipazine	0-9	growth hormone 1	Homo sapiens	60-62
2853663-7	1987	Quipazine injected iv at .1 or .5 mg/kg BW increased plasma GH (P less than .05) and ACTH (P less than .001) concentrations.	Quipazine	0-9	proopiomelanocortin	Homo sapiens	85-89
2853663-8	1987	There was a dose effect of quipazine on both GH (P less than .05) and ACTH (P less than .0001) secretion.	Quipazine	27-36	growth hormone 1	Homo sapiens	45-47
2853663-8	1987	There was a dose effect of quipazine on both GH (P less than .05) and ACTH (P less than .0001) secretion.	Quipazine	27-36	proopiomelanocortin	Homo sapiens	70-74
2853663-9	1987	Pretreatment of steers with cyproheptadine (.06 and .6 mg/kg BW) reduced the stimulation of GH by quipazine (P less than .0001) and decreased basal GH concentrations (P less than .0004).	Quipazine	98-107	growth hormone 1	Homo sapiens	92-94
2853663-10	1987	Cyproheptadine at .06 mg/kg BW did not alter quipazine effects on ACTH, however, the higher dose decreased the peak ACTH response (P less than .02) to quipazine.	Quipazine	151-160	proopiomelanocortin	Homo sapiens	116-120
22158750-4	1987	The preferential 5-HT(1B) agonists RU-24969 and quipazine induced anorexia in unstressed rats and tended to supplement the anorectic effects of stress.	Quipazine	48-57	5-hydroxytryptamine receptor 1B	Rattus norvegicus	17-24
4041865-5	1985	5-HT, bufotenine, N,N-dimethyltryptamine (DMT) and quipazine were only slightly more potent at the 5-HT1A binding site.	Quipazine	51-60	5-hydroxytryptamine receptor 1A	Bos taurus	99-105
3877146-10	1985	Furthermore quipazine, in concentrations that preferentially interact with the 5-HT1B subtype, antagonized the actions of exogenous 5-HT on K+-stimulated release.	Quipazine	12-21	5-hydroxytryptamine receptor 1B	Homo sapiens	79-85
2882436-2	1986	Both beta 1-and beta 2-adrenoceptor agonists potentiated the head-twitch induced by quipazine in sham-operated controls.	Quipazine	84-93	adrenoceptor beta 1	Rattus norvegicus	5-35
2943219-8	1986	In contrast, putative 5-HT1B agonists (i.e. RU-24969 and quipazine) decrease feeding and cause anorexia.	Quipazine	57-66	5-hydroxytryptamine receptor 1B	Rattus norvegicus	22-28
3859879-8	1985	These data suggest that the behavioral disruption induced by these hallucinogens and quipazine relates at least in part to an effect on 5HT2 receptors, while the effects of lisuride do not involve a significant interaction at the 5HT2 receptor.	Quipazine	85-94	5-hydroxytryptamine receptor 2A	Homo sapiens	136-149
2931284-2	1985	For this purpose plasma ADH levels were measured in rats treated with drugs enhancing 5-HT transmission, such as d-fenfluramine and quipazine and with 5-HT depleting drugs, p-chlorophenylalanine (PCPA) and 5,7-dihydroxytryptamine (5,7-DHT).	Quipazine	132-141	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	24-27
2931284-4	1985	d-Fenfluramine and quipazine induced dose-related increases in plasma ADH levels in normohydrated rats.	Quipazine	19-28	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	70-73
6148678-0	1984	Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release: evidence for serotonin-catecholamine interactions.	Quipazine	34-43	prolactin	Rattus norvegicus	72-81
6148678-1	1984	The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems.	Quipazine	74-91	prolactin	Rattus norvegicus	147-156
6148678-1	1984	The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems.	Quipazine	74-91	prolactin	Rattus norvegicus	158-161
6148678-2	1984	Quipazine (15 mg/kg, ip) significantly reduced LH and increased PRL when administered to ovariectomized rats.	Quipazine	0-9	prolactin	Rattus norvegicus	64-67
6206407-2	1984	The influence of DU 24565 and quipazine on the activity of MAO was studied in rat brain homogenates, using labelled serotonin as a substrate.	Quipazine	30-39	monoamine oxidase A	Rattus norvegicus	59-62
6235145-0	1984	Prolactin and luteinizing hormone levels of prelaying, laying and postlaying turkey hens following central administration of serotonin and peripheral administration of quipazine maleate.	Quipazine	168-185	prolactin	Meleagris gallopavo	0-9
6144226-3	1984	Serotonin and its agonist quipazine stimulated the release of Prl and inhibited release of GH in a concentration-related manner.	Quipazine	26-35	prolactin	Homo sapiens	62-65
6610456-4	1984	Serum prolactin elevations produced by quipazine, a direct acting 5-HT agonist, were not significantly affected by MR lesions.	Quipazine	39-48	prolactin	Rattus norvegicus	6-15
6144226-4	1984	The antagonist methysergide blocked the effects of serotonin and quipazine on Prl.	Quipazine	65-74	prolactin	Homo sapiens	78-81
6540015-7	1984	The same dose of CCK-4 also decreased the intensity of quipazine (2,5 mg/kg) head-twitches.	Quipazine	55-64	protein tyrosine kinase 7 (inactive)	Homo sapiens	17-22
6616203-5	1983	The biphasic effect of 5-MeODMT on rat PRL secretion is shared by the centrally-acting 5-HT agonist quipazine, but not by 5-MeOT, an indole derivative excluded by the blood-brain barrier.	Quipazine	100-109	prolactin	Rattus norvegicus	39-42
6230284-2	1983	Quipazine (0.1-10.0 mg/kg), a serotonin (5-hydroxytryptamine; 5-HT) agonist, induced a dose-dependent rise in serum PRL level 1 hr after injection.	Quipazine	0-9	prolactin	Meleagris gallopavo	116-119
6230284-7	1983	Prior injection of 20 mg/kg MES completely blocked the serum PRL rises induced by quipazine and 5-HTP.	Quipazine	82-91	prolactin	Meleagris gallopavo	61-64
6628538-5	1983	These results suggest that serotonergic stimulation of rat PRL secretion by quipazine and 5-MeODMT may be partially mediated by 5-HT2 receptors.	Quipazine	76-85	prolactin	Rattus norvegicus	59-62
510375-1	1979	Repeated administration of 5-methoxy-N,N-dimethyltryptamine (5MeODMT, 5 mg/kg, a serotonin agonist, every 3 h for a total of 4 injections) potentiated its prolactin (PRL)-releasing effect and that of two other serotonin agonists, quipazine and N,N-dimethyltryptamine.	Quipazine	230-239	prolactin	Rattus norvegicus	155-164
6457138-6	1981	p-Chloroamphetamine and quipazine produced dose-dependent increases in plasma renin activity and plasma corticosterone.	Quipazine	24-33	renin	Rattus norvegicus	78-83
6457138-7	1981	The increase in plasma renin activity produce by quipazine was more rapid than that produced by p-chloroamphetamine.	Quipazine	49-58	renin	Rattus norvegicus	23-28
6785814-5	1981	The increase in serum prolactin concentration elicited by administration of the serotonergic agonists quipazine or 5-methoxy-N,N-dimethyltryptamine and by the serotonin uptake inhibitor fenfluramine also was potentiated by pretreating rats with 5,7-DHT.	Quipazine	102-111	prolactin	Rattus norvegicus	22-31
6974213-5	1981	The serotonin receptor agonist, quipazine, resulted in a marked increase in plasma prolactin and a marked reduction in plasma GH concentrations in untreated birds.	Quipazine	32-41	prolactin	Homo sapiens	83-92
6974213-6	1981	In pCPA-pretreated animals quipazine was no longer effective in altering plasma prolactin levels but still caused a significant drop in circulating levels of GH.	Quipazine	27-36	prolactin	Homo sapiens	80-89
6971560-3	1981	Amitriptyline, doxepin, iprindole, mianserin and trazadone inhibited the prolactin stimulating effects of high doses of 5-HTP and quipazine, suggesting that these drugs have 5-HT receptor blocking properties.	Quipazine	130-139	prolactin	Rattus norvegicus	73-82
143671-3	1977	LSD was more potent than methysergide, a serotonin receptor blocker, in lowering plasma PRL levels and more potent than apomorphine, a known direct acting dopamine agonist, in blocking the increase in plasma PRL produced by quipazine, a 5-HT agonist.	Quipazine	224-233	prolactin	Rattus norvegicus	208-211
487124-0	1979	Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.	Quipazine	106-115	prolactin	Rattus norvegicus	76-85
485703-2	1979	We have examined the effect of quipazine, a drug which has been reported to increase plasma PRL levels by acting through a serotonergic mechanism, on PRL release in rats pretreated with penfluridol or alpha-methyl-p-tyrosine (alpha-MPT).	Quipazine	31-40	prolactin	Rattus norvegicus	92-95
485703-2	1979	We have examined the effect of quipazine, a drug which has been reported to increase plasma PRL levels by acting through a serotonergic mechanism, on PRL release in rats pretreated with penfluridol or alpha-methyl-p-tyrosine (alpha-MPT).	Quipazine	31-40	prolactin	Rattus norvegicus	150-153
485703-5	1979	Quipazine also increased plasma PRL levels in normal male rats.	Quipazine	0-9	prolactin	Rattus norvegicus	32-35
149011-5	1978	or p-chlorophenylalanine (100 mg/kg X 3, orally) pretreatment markedly blocked the prolactin-releasing effect of both d-fenfluramine and quipazine.	Quipazine	137-146	prolactin	Rattus norvegicus	83-92
994712-0	1976	Effect of quipazine on rat plasma prolactin levels.	Quipazine	10-19	prolactin	Rattus norvegicus	34-43
401022-5	1977	In addition, the serotonin agonist quipazine elevated significantly serum prolactin levels in male and female rats.	Quipazine	35-44	prolactin	Rattus norvegicus	74-83
33792624-7	2021	Connectivity map have identified five drugs (levobunolol, NU-1025, quipazine, anisomycin and sulfathiazole) for CAHM targeted therapy in THCA.	Quipazine	67-76	colon adenocarcinoma hypermethylated	Homo sapiens	112-116
28004950-1	2017	Quipazine is a 5-HT2A-receptor agonist that has been used to induce motor activity and promote recovery of function after spinal cord injury in neonatal and adult rodents.	Quipazine	0-9	5-hydroxytryptamine receptor 2A	Rattus norvegicus	15-21
33754011-8	2021	CMap analysis revealed that quipazine and terazosin may be targeted drugs for UXT-AS1 in PDAC.	Quipazine	28-37	UXT antisense RNA 1	Homo sapiens	78-85
32122737-4	2020	Among these compounds, S1, as a D2 receptor partial agonist, demonstrated very potent inhibition of quipazine-induced head-twitch response, which validated its 5-HT2A receptor antagonistic efficacy in vivo.	Quipazine	100-109	5-hydroxytryptamine receptor 2A	Homo sapiens	160-175
19019202-6	2008	Behavioral and kinematic analyses revealed quipazine-induced LM in 1-week Tx mice either non-pretreated or pretreated with selective 5-HTR(2B) and/or 5-HTR(2C) antagonists.	Quipazine	43-52	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	150-158
25151623-7	2014	Following treatment with quipazine, there was an increase in both fore- and hindlimb total movement and alternated steps in P1 and P10 pups.	Quipazine	25-34	perforin 1	Rattus norvegicus	124-134
19502168-8	2009	RESULTS: Compared with the control group, the viability of L-02 cells was improved in the 10, 50, and 250 microg/ml quipazine groups (P<0.05); the percentage of S-phase and PCNA-positive cells were increased in the 2, 10, 50, and 250 microg/ml quipazine groups (P>0.05); and no difference in the percentage of apoptotic cells was found between the 50 microg/ml quipazine and control groups (P>0.05).	Quipazine	116-125	proliferating cell nuclear antigen	Homo sapiens	176-180
23822584-4	2013	KEY RESULTS: Dopamine, quipazine and VUF10166 were partial agonists at wild type 5-HT3A and 5-HT3AB receptors, with quipazine and VUF10166 causing a long-lived (>20 min) inhibition of subsequent agonist responses.	Quipazine	23-32	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
23822584-6	2013	A T6"S substitution in the 5-HT3A subunit decreased EC50 and increased Rmax of dopamine and quipazine at both homomeric and heteromeric receptors.	Quipazine	92-101	5-hydroxytryptamine receptor 3A	Homo sapiens	27-33
23822584-8	2013	CONCLUSIONS AND IMPLICATIONS: These results indicate that a mutation in the pore lining domain in both 5-HT3A and 5-HT3AB receptors alters the relative efficacy of a series of agonists, changing some (e.g. quipazine) from apparent antagonists to potent and efficacious agonists.	Quipazine	206-215	5-hydroxytryptamine receptor 3A	Homo sapiens	103-115
22309909-1	2012	It is well known that 6-nitroquipazine exhibits about 150-fold higher affinity for the serotonin transporter (SERT) than quipazine and recently we showed quipazine buspirone analogues with high to moderate SERT affinity.	Quipazine	29-38	solute carrier family 6 member 4	Homo sapiens	87-108
22309909-1	2012	It is well known that 6-nitroquipazine exhibits about 150-fold higher affinity for the serotonin transporter (SERT) than quipazine and recently we showed quipazine buspirone analogues with high to moderate SERT affinity.	Quipazine	29-38	solute carrier family 6 member 4	Homo sapiens	110-114
22309909-1	2012	It is well known that 6-nitroquipazine exhibits about 150-fold higher affinity for the serotonin transporter (SERT) than quipazine and recently we showed quipazine buspirone analogues with high to moderate SERT affinity.	Quipazine	29-38	solute carrier family 6 member 4	Homo sapiens	206-210
22309909-3	2012	Unexpectedly, their SERT binding affinities were moderate, and much lower than that of the previously studied quipazine buspirone analogues.	Quipazine	110-119	solute carrier family 6 member 4	Homo sapiens	20-24
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	Quipazine	173-182	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	Quipazine	184-193	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100